Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts
Boston Scientific shares rose 1.3% to $92.51 Friday after Fitch upgraded its outlook to Positive, keeping A-/F1 ratings unchanged. The move follows Boston Scientific’s $14.5 billion Penumbra acquisition announcement. Trading volume topped recent averages. Investors await earnings and deal updates at the Feb. 4 call.